重症肺炎合并糖尿病患者的临床治疗措施分析

Analysis of Clinical Treatment of Severe Pneumonia Complicated with Diabetes Mellitus

目的探讨氨溴索辅助治疗重症肺炎合并糖尿病的临床疗效。方法使用随机数字表法将2014年6月—2015年6月收治的120例重症肺炎合并糖尿病患者分为研究组和对照组(各60例),对照组患者常规应用抗生素、胰岛素进行治疗,研究组在常规治疗基础上加用氨溴索,观察两组患者的临床疗效。结果研究组患者的肺部炎症控制时间、住院时间均显著短于对照组(P<0.05);研究组的治愈率为36.67%,显著高于对照组的21.67%(P<0.05);研究组的总有效率为91.67%,显著高于对照组的66.67%(P<0.05);研究组的病死率显著低于对照组,病灶吸收率显著高于对照组(P<0.05);两组的不良反应发生率比较无明显差异(P>0.05)。结论临床应用氨溴索辅助治疗重症肺炎合并糖尿病,能有效缓解临床症状,加快病灶吸收,提高临床疗效,临床应用优势显著,值得推广。

Objective To evaluate the clinical efficacy of severe pneumonia and diabetes with ambroxol adjuvant treatmen.Methods 120 patients of severe pneumonia and diabetes were divided into study group and the control group（60 cases） by a random number table, The control group used of antibiotics and insulin routine treatment, study group with ambroxol on conventional treatment, observed the clinical efficacy of the two groups of patients. Results Lung inflammation control time and hospitalization time of study group were significantly shorter than the control group（P0.05）; the cure rate of the study group was 36.67%, significantly higher than the 21.67% of control group（P0.05）; the total effective of study group was91.67%, significantly higher than the 66.67% of control group（P0.05）; mortality rate of study group was significantly lower than the control group, focus absorption rate was significantly higher（P0.05）; there was no significant difference（P0.05）incidence of adverse reactions between the two groups. Conclusion Use ambroxol adjuvant treatment of severe pneumonia and diabetes, can effectively relieve symptoms, lesions accelerate absorption and improve clinical efficacy. It has significant clinical advantages, should be promoted.